Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Bruce Rosen who wrote (1154)	12/20/1997 2:32:00 AM
From: Bill Wexler	Read Replies (2) \| Respond to of 7041

Zonagen lie #3: Bruce Rosen states the following: <<They have a unique formulation of phentolamine called Vasomax..>> Zonagen's drug is phentolamine mesylate. It is not unique. fda.gov Do a search for the word "phentolamine" or "regitine".

To: Bruce Rosen who wrote (1154)	12/20/1997 12:14:00 PM
From: BDR	Read Replies (2) \| Respond to of 7041

<<They have a unique formulation of phentolamine called Vasomax. >> That may be true but without patent protection that means very little. As I look at ZONA (I still have no position) it appears to be a very high risk investment vehicle for eaither longs or shorts, to say the least. However, at its current price without a proprietary product, without FDA approval for that product, without even a NDA filed for that product, and with a major pharmaceutical industry player with a similar (in concept) product well ahead in the testing, review, approval, manufacturing, distribution, and sales force areas I would have to say the riskier position by far is that of the longs. <<Many companies announce stock buybacks. It happens all the time, often with excellent results. >> Usually companies that buy back their shares have products, revenues and profits. And usually they haven't just issued new shares to raise the capital they will use in the share buy-back. I am not saying that ZONA is a scam. I just think they have made some very odd management decisions.